The co-activator Yorkie (Yki) mediates transcriptional regulation effected by the Drosophila Fat-Warts (Wts)-Hippo (Hpo) pathways. Yki is inhibited by Wts-mediated phosphorylation, and a Wts phosphorylation site at Ser168 has been identified. Here we identify two additional Wts phosphorylation sites on Yki, and examine the respective contribution of all three sites to Yki nuclear localization and activity. Our results show that although Ser168 is the most critical site, all three phosphorylation sites influence Yki localization and activity in vivo, and can be sites of regulation by Wts. Thus, investigations of the role of Yki and its mammalian homolog Yesassociated protein (YAP) in development and oncogenesis should include evaluations of additional sites. The WW domains of Yki are not required for its phosphorylation, but instead are positively required for its activity. We also identify two potential sites of phosphorylation by an unknown kinase, which could influence phosphorylation of Ser168 by Wts, suggesting that there are additional mechanisms for regulating Yki/YAP activity.
Introduction
Investigations of how growth is controlled during development in model systems have resulted in the identification of genes that can act as tumor suppressors or oncogenes in humans (reviewed in Vidal and Cagan, 2006) . Fat-Hippo (Hpo)-Warts (Wts) signaling comprises a set of genes that function within the interconnected Fat-Wts and Hpo-Wts pathways to regulate growth (reviewed in Reddy and Irvine, 2008) . Mutation or dysregulation of these genes can result in tumor formation, both in Drosophila and in mammals (reviewed in Reddy and Irvine, 2008; Zeng and Hong, 2008) . A transcriptional co-activator protein, called Yorkie (Yki) in Drosophila and Yes-associated protein (YAP) in mammals, acts as the key effector of FatHpo-Wts signaling. YAP has been implicated as an oncogene in liver, mammary and prostate tumors, and upstream regulators of YAP have been implicated as tumor suppressors in soft-tissue sarcomas, ovarian tumors, neurofibromas, melanomas and mammary carcinomas. Understanding the mechanisms that regulate Yki/YAP activity is thus important to a wide range of cancers.
Upstream components of Fat-Hpo-Wts signaling converge on a kinase, known as Wts in Drosophila and as Lats1 and Lats2 in mammals (reviewed in Reddy and Irvine, 2008) . Wts is made in an inactive form, and is activated by phosphorylation and association with a cofactor, Mob as tumor suppressor (Mats). Activation of Wts is promoted by another kinase, Hpo, which phosphorylates Wts, Mats and a scaffolding protein called Salvador (Sav) . The activity of Hpo is promoted by two membrane-associated FERM domain proteins, Merlin and Expanded (Ex) .
Yki/YAP is a non-DNA-binding transcriptional co-activator, but interacts with the Sd protein in Drosophila, and homologs of Sd in mammals, the TEF/TEAD proteins (Goulev et al., 2008; Wu et al., 2008; Zhang et al., 2008; Zhao et al., 2008) . Sd/TEAD provides DNA-binding activity, and also promotes nuclear localization of unphosphorylated Yki/YAP. Investigations of the regulation of Yki and YAP by Wts/Lats identified a critical Ser residue, Ser168 of Yki (Ser127 of YAP) (Dong et al., 2007; Zhao et al., 2007; Hao et al., 2008; Oh and Irvine, 2008; Zhang et al., 2008) . Phosphorylation of this Ser creates a binding site for 14-3-3 proteins (Basu et al., 2003; Dong et al., 2007; Zhao et al., 2007; Oh and Irvine, 2008) , a class of proteins that anchor phosphoproteins in the cytoplasm (Mackintosh, 2004) . Thus, Wts inhibits Yki activity at least in part by excluding it from the nucleus. Although Ser168 is a critical Wts phosphorylation site, several observations indicate that additional sites contribute to Yki regulation. Direct examination of Yki phosphorylation in vivo showed that there are multiple Wts sites (Oh and Irvine, 2008) . Similarly, studies of YAP phosphorylation in cultured cells identified multiple Lats sites (Zhao et al., 2007; Hao et al., 2008) . Moreover, mutation of Yki Ser168 or YAP Ser127 reduced, but did not eliminate, their sensitivity to Wts/Lats (Zhao et al., 2007; Hao et al., 2008; Oh and Irvine, 2008) . Studies in mammalian cells identified a consensus phosphorylation sequence, HX(R/H/K)XX(S/T), and mutation of all five consensus sites further reduced the sensitivity of YAP to Lats in cultured cell assays (Zhao et al., 2007; Hao et al., 2008) . However, the respective contributions and mechanism of action of the additional sites have not been examined in detail. Here, we use cell culture and in vivo assays in Drosophila to characterize the contributions of all of the Wts phosphorylation sites to Yki activity, to evaluate the roles of the WW domains, and to identify a potential new mechanism of Yki regulation.
Results
Ser111 and Ser250 of Yki are phosphorylated by Wts in S2 cells Drosophila Yki contains three potential Wts/Lats phosphorylation sites, at amino acids 111, 168 and 250 ( Figure 1a ) (Zhao et al., 2007; Hao et al., 2008) . Phosphorylation of Ser168 has been established (Dong et al., 2007; Oh and Irvine, 2008) . To determine whether Ser111 and Ser250 are phosphorylated, Ser to Ala mutations were introduced, and the resulting Yki isoforms were expressed in cultured Drosophila S2 cells. Their mobility was then compared on Phos-tag gels, which incorporate a phosphate-binding compound that retards the mobility of phosphorylated proteins in proportion to their degree of phosphorylation (Kinoshita et al., 2006; Oh and Irvine, 2008) . In the presence of exogenous Wts, together with its activators Hpo and Sav, Yki is phosphorylated. This can be visualized by a decrease in the mobility of an epitope-tagged form of Yki, Yki:V5, as compared with phosphatase-treated Yki:V5, or Yki:V5 without exogenous, activated Wts (Figure 1b) . Single Ser to Ala mutations at consensus Wts phosphorylation sites (S111A, S168A and S250A) each resulted in less mobility shift compared with wildtype Yki:V5, although their mobilities were still retarded compared with phosphatase-treated Yki:V5 (Figure 1b) . Thus, Ser111, Ser168 and Ser250 are all Wts sites.
Each of the possible pair-wise combinations of Ser to Ala mutations was also examined, and they exhibited a reduced shift compared with the single mutants ( Figure 1b) . The mobility of the S111A, S168A S250A triple mutant was not retarded at all by co-expression of Hpo, Sav and Wts. A fraction of triple mutant Yki was detected in a faster mobility band on Phos-tag gels, which is also detected upon phosphatase treatment of wild-type Yki. Although the basis for this isoform has not yet been identified, the observation that the mobility of the Yki:V5 S111A,S168A,S250A triple mutant is unaffected by co-expression with activated Wts, or by phosphatase treatment, implies that Ser111, Ser168 and Ser250 are the only Wts phosphorylation sites in Yki.
Nuclear localization of Yki is prevented through phosphorylation of Ser168 and subsequent interaction with 14-3-3 proteins (Basu et al., 2003; Dong et al., 2007; Zhao et al., 2007; Oh and Irvine, 2008) . In S2 cells, wildtype Yki:V5 is predominantly cytoplasmic, but faint staining is detectable in the nucleus (Figure 1c ). Cotransfection of Hpo, Sav and Wts eliminated detectable nuclear staining of Yki:V5 (Figure 1d ). Yki:V5 S168A exhibited slightly increased nuclear staining in S2 cells compared with wild-type Yki:V5 (Figure 1e ), but in the presence of activated Wts nuclear localization of Yki:V5 S168A was almost undetectable (Figure 1f ), consistent with the observation that the activity of Yki:V5 S168A can be inhibited by overexpression of Hpo and Wts in vivo (Oh and Irvine, 2008) . The Yki: V5 S111A,S168A,S250A triple mutant appears equally distributed between the cytoplasm and the nucleus (Figure 1g ). In the presence of Hpo, Sav and Wts, substantial nuclear localization of Yki:V5 S111A,S168A,S250A remained ( Figure 1h ). Thus, Ser111 and Ser250 contribute to the regulation of Yki localization.
Two mechanisms that influence the nuclear localization of Yki/YAP have been described. One is the binding to 14-3-3 proteins; the other is the interaction with Sd/TEAD, which promotes nuclear localization (Goulev et al., 2008; Wu et al., 2008; Zhang et al., 2008; Zhao et al., 2008) . To investigate whether phosphorylation of Ser residues in Yki might decrease nuclear localization by inhibiting binding to Sd, we carried out co-immunoprecipitation experiments, but mutation of Ser168 had no effect on Sd-Yki binding, either in the presence or in the absence of activated Wts (Figure 1i ). The Yki:V5 S111A,S168A,S250A triple mutant and Yki:V5 S111A,S250A double mutant also exhibited similar binding to Sd, regardless of the expression of exogenous Wts (Figure 1i ).
Ser111 and Ser250 influence Yki activity in vivo
The influence of the S111A and S250A mutations on Yki in S2 cells suggested that Yki could be regulated through these sites in vivo. This was investigated by introducing mutant isoforms of Yki:V5 into a UASyki:V5 transgene. As different chromosomal insertions can result in different levels of expression, we used phiC31-mediated site-specific transformation to insert all of the UAS-yki:V5 transgenes into the same chromosomal location (attP2 at 68A) (Groth et al., 2004) , such that their expression levels would be the same. The activity of wild-type UAS-yki:V5[attP68A] was confirmed by its ability to rescue the growth of yki The activities of mutant forms of Yki were then compared by expressing them in eyes, using GMR-Gal4, or in wings, using sd-Gal4. Expression of wild-type Yki:V5 did not cause evident phenotypes (Figures 2b  and 3b ), indicating that Yki expression, although above endogenous levels, was low enough to be repressed by endogenous upstream tumor suppressors. When Yki:V5 mutant proteins were expressed, overgrowth phenotypes and reduced viability were observed. The different isoforms could be arranged into a phenotypic series. Under GMR-Gal4 control, the relative phenotypic strength observed was wild type ¼ S111AoS250A (increase in eye size) oS111A,S250A (greater increase in eye size, but eye mostly flat) oS168A (eye enlarged Phosphatase S168A S111A S111A,S168A S250A S168A,S250A S111A,S250A S111A,S168A,S250A
Yki:V5 + GFP:V5 S168A S111A,S250A S111A,S168A,S250A and folded owing to extensive overgrowth) oS111A, S168A ¼ S168A,S250A (eye greatly enlarged and folded, and viability reduced) oS111A, S168A,S250A (viability greatly reduced, eye enlarged and highly folded in surviving flies) (Figures 3b-i) . With sd-Gal4 the allelic series was wild type oS111A (slightly enlarged wings) oS250A (enlarged wings) oS111A,S250A (distorted wings and low viability) oS168A ¼ S111A,S168A ¼ S168A,S250A (extended third instar larval stage and eventual late larval lethality) oS111A,S168A,S250A (early larval lethality) (Figures 2b-f and data not shown). The wing-specific driver vg-Gal4 was also lethal in combination with all of the Yki:V5 isoforms that included the S168A mutation.
Some of the mutants were only subtly different from each other, but we reasoned that overexpression might obscure differences in activity. Thus we reduced expression levels by co-expressing the Gal4 antagonist Gal80 (Lee and Luo, 2001) . In animals containing a single copy of tub-Gal80 and two copies of GMR-Gal4, the S168A mutant exhibited only a subtle eye overgrowth ( Figure 3k ). However, S111A, S168A and S250A mutants exhibited obvious eye overgrowth ( Figure 3l ). Thus, at these low expression levels, mutation of Ser168 alone only slightly enhances Yki activity. Moreover, at low levels of expression, mutation of Ser111 and Ser250 can make critical contributions to the regulation of Yki activity even when Ser168 is already mutant.
Yki Ser111 and Ser250 are sites of Wts regulation in vivo
To further explore the activities of Yki:V5 isoforms, they were co-expressed with Hpo, or Hpo and Wts together, under GMR-Gal4 control. This resulted in a phenotypic series in which wild type (pupal lethal with hpo or with hpo and wts) oS111A (very small eyes with hpo, lethal with hpo and wts) oS250A (small eyes with hpo, lethal with hpo and wts) o S111A,S250A (small eyes with hpo, very small eyes with hpo and wts) oS168A (greatly enlarged eyes with hpo, enlarged eyes with hpo and wts) oS111A,S168A ¼ S168A,S250A (greatly enlarged eyes with hpo or with hpo and wts, but less so than in the absence of hpo and wts overexpression) oS111A,S168A,S250A (enlarged and highly folded eyes with hpo or hpo and wts, but viability increased compared with animals without hpo and wts overexpression) (Figures 3m-w and data not shown). Thus, all three Wts phosphorylation sites can influence the sensitivity of Yki to Wts in vivo.
We observed earlier that expression of Yki activated by mutation of Ser168 (Yki-S168A:GFP) under actGal4 control resulted in larger, rounder clones (Oh and Irvine, 2008) . Co-overexpression of Hpo and Wts suppressed the growth of Yki-S168A:GFP-expressing clones. To examine whether this could be explained by phosphorylation of Ser111 and Ser250, Yki:V5 isoforms were expressed in clones of cells under act-Gal4 control in the presence or absence of Hpo and Wts. Yki:V5-expressing clones seemed to have wild-type size and shape (Figure 4a ), but Yki:V5 S111A,S250 double mutant clones were rounder, consistent with the observation that mutation of these sites activates Yki (Figure 4c ). However, Yki:V5 S111A,S250 clones did not survive well in the presence of Hpo and Wts (Figure 4d ), indicating that this double mutant can still be repressed by Wts. In contrast to our earlier results with Yki-S168A:GFP, when Yki:V5 S168A was co-expressed with Hpo and Wts, large round clones were still observed ( Figure 4f ). However, when another upstream tumor suppressor, Ex, was also co-expressed with Hpo and Wts in Yki:V5 S168A -expressing clones, the size and number of clones were decreased (Figure 4g ), indicating that the resistance of Yki:V5 S168A to inactivation by upstream tumor suppressors can be overcome by increasing pathway activation. By contrast, cells expressing the Yki:V5 S111A,S168A,S250A triple mutant made large round clones even in the presence of Ex, Hpo and Wts (Figure 4h) . Thus, the Yki:V5 S111A,S168A,S250A triple mutant is less sensitive to upstream tumor suppressors than Yki:V5 S168A . S111A and S250A mutations affect the nuclear localization of Yki in vivo Earlier, we observed that mutation of Ser168 resulted in a modest but consistent effect on the nuclear localization of Yki in imaginal disc cells (Oh and Irvine, 2008) . The influence of Ser111 and Ser250 on Yki localization in imaginal discs was examined by expressing Yki:V5 mutant isoforms in clones. Yki:V5 and Yki:V5 S111A were predominantly cytoplasmic (Figure 5a and data not shown), with faint nuclear staining, similar to endogenous Yki or Yki:GFP (Oh and Irvine, 2008) . Yki:V5 S250A exhibited mildly enhanced nuclear localization (Figure 5b ), and the Yki:V5 S111A,S250A double mutant exhibited still more nuclear localization (Figure 5c ), which suggests that its hyperactivity is caused by enhanced nuclear localization. Although the effect seems subtle, it was confirmed by quantitative image analysis ( Figure 5r ). Enhanced nuclear localization of Yki:V5 S111A,S250A was also evident when it was coexpressed with Sd (Figure 5f ). Nuclear localization of Yki:V5 S168A was even greater than for Yki:V5 S111A,S250A
, both with and without Sd (Figures 5d, g and r) , indicating that Ser168 is the most important phosphorylation site for regulation of Yki localization.
Even though the size and shape of Yki:V5 S168A clones was not obviously affected by co-expression of Hpo and Wts, its nuclear localization was decreased (Figure 5h) . Thus, Yki:V5 S168A expression is high enough that clone growth is not dramatically impaired by Hpo and Wts, but Yki:V5 S168A protein is still affected. By contrast, Yki nuclear localization in clones expressing the Yki:V5 S111A,S168A,S250A triple mutant with Hpo and Wts Yki β-gal Yki:V5 S250A S111A S169D,172D S169A,172A -WW S111A,S168A,S250A-WW S111A :V5, (e) UAS-yki S169A,S172A :V5, (f) UAS-yki S250A :V5 (g) UAS-yki S169DS172D :V5, (h) UAS-yki ÀWW :V5 and (g) UAS-yki S111A S168A S250A ÀWW :V5.
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Yorkie phosphorylation sites H Oh and KD Irvine was similar to that in clones without Hpo and Wts (Figures 5i and j) . However, when Ex was also co-expressed with Hpo and Wts, Yki:V5 S111A,S168A,S250A nuclear localization seemed to decrease, although the clones still tended to overgrow (Figure 5k ). Expression of Ex alone did not seem to affect Yki:V5 S111A,S168A,S250A localization ( Figure 5l ). These results are consistent with the conclusion that the Yki:V5 S111A,S168A,S250A triple mutant is less sensitive to the upstream tumor suppressors than Yki:V5 S168A and, thus, that phosphorylation at Ser111 and Ser250 by Wts can regulate Yki independently of Ser168. They further suggest that there might be an additional mechanism by which Ex, Hpo and Wts can inhibit Yki. This additional mechanism does not involve Yki phosphorylation, as it could affect the Yki triple mutant; yet, expression of Ex alone or in combination with Wts and Hpo did not detectably affect Yki:V5 S111A,S168A,S250A phosphorylation (Supplementary Figure S1 ).
Phosphorylation of Ser111 and Ser250 influences phosphorylation of Ser168
The detection of three Wts phosphorylation sites within Yki raises the question of whether or not they are each regulated independently. To investigate this, we used a phospho-specific antibody that detects Ser168 phosphorylation (Dong et al., 2007) . In S2 cells with exogenous Hpo, Sav and Wts, the level of Ser168 phosphorylation was slightly decreased for Yki:V5 S111A , Yki:V5 S250A or Yki:V5-S111A,S250A
mutants compared with wild-type Yki:V5 (Figure 6a ). Consistent with this, the association between Yki:V5 isoforms and 14-3-3 proteins was also reduced (Figure 6a ). To characterize the influence of S111A and S250A mutations in vivo, we examined Ser168 phosphorylation in extracts of fly head from animals in which Yki mutant isoforms were expressed under GMR-Gal4 control. Decreased Ser168 phosphorylation was clearly observed in Yki:V5 S111A,S250A and Yki:V5 S250A mutants (Figure 6b ). The effect was even more obvious than in S2 cells, possibly because of the limiting levels of endogenous upstream tumor suppressors. These results imply that Wts phosphorylation of Yki is cooperative. They also imply that the hyperactivity of S111A and S250A yki mutants in vivo might be partly because of decreased phosphorylation of Ser168. Nonetheless, the comparisons of S168A single mutants with double and triple mutants indicate that phosphorylation of Ser111 and Ser250 can also influence Yki activity independently of their effect on Ser168.
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Role of the WW domains in Yki activity
Yki was first identified as a Wts-binding protein, and it associates with Wts through a WW domain-PPXY motif interaction (Huang et al., 2005) . However, a fragment of Yki that lacks the WW domains (Yki-N) was still phosphorylated by Wts (Oh and Irvine, 2008) . To evaluate the role of the WW domains, four point mutations, which abolish interaction with Wts (Huang +Wts+Hpo S168A S111A,S168A,S250A + Sd S169D,172D S111A,S250A Yki:V5 S168A + Sd + Sd S111A,S168A,S250A S111A,S168A,S250A +Wts+Hpo +Wts+Hpo + Ex S111A,S250A S168A Yki:V5 S250A -WW S111A,S168A,S250A-WW S111A,S168A,S250A S111A,S168A,S250A- ÀWW was still phosphorylated by Wts, both in S2 cells (Figure 6a) , and in vivo (Figure 6c) , and overexpression of Yki:V5 ÀWW did not promote overgrowth (Figure 2h ), as would have been expected if phosphorylation were impaired. Instead, the WW domains are positively required for Yki activity, because Yki:V5 ÀWW expressed under arm-Gal4 control could not rescue yki B5 mutants, and when the WW mutations were introduced into the S111A,S168A,S250A triple mutant (Yki:V5 S111A,S168A,S250AÀWW ), no overgrowth was induced by expression under GMR-Gal4 control (Figure 3x ), and only a very mild overgrowth was induced under sd-Gal4 control (Figure 2i ). The WW domains are not required for interaction with Sd (Figure 1i) . Indeed, when Yki:V5 S111A,S168A,S250AÀWW was co-expressed with Sd, it was predominantly nuclear (Figure 5p ), but inactive, as clones were irregular and small. The inactivity of Yki isoforms with WW domain mutations was also evidenced by the inability of Yki:V5 S111A,S168A,S250AÀWW to promote the transcription of a Yki-responsive reporter construct (Zhang et al., 2008) in imaginal discs (Figure 7b) . Moreover, mutation of the WW domains rendered Yki inactive in a Sd-independent cell-based Phos-Tag anti-V5 S168A S111A S111A,S168A S250A S168A,S250A S111A,S250A S111A,S168A,S250A + S169A,S172A Yki-N S169A,S172A Yki-N:V5 Yki-N:V5
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anti-V5 GMR heads -WW Figure 6 Influence of other phosphorylation sites on Ser168 phosphorylation. (a) Western blots (4-15% gels) of samples from S2 cells co-transfected to express 14-3-3e:FLAG, 14-3-3z:FLAG, Wts, Hpo, Sav, and GFP:V5 or Yki:V5 isoforms. The top two panels show (Input) show blots on cell lysate, using anti-FLAG (14-3-3) or anti-V5 (GFP or Yki), and the bottom three panels (V5 IP) show blots on material precipitated by anti-V5 beads. 14-3-3e and z have similar mobilities and were not separated. (b, c) Western blots on lysates of adult heads from animals expressing UAS-yki:V5 isoforms under GMR-Gal4 control. The top and bottom panels show the same membrane, blotted with anti-V5 and anti-Yki-S168P, respectively. (Input) show blots on cell lysates, using anti-V5 (Yki); the uppermost panel is a Phos-tag gel (25 mM Phos-tag) and below is a 4-15% SDS-PAGE gel. The bottom two panels (V5 IP) show blots on material precipitated by anti-V5 beads, and run on 4-15% gels, using anti-V5 or anti-Yki-S168P, as indicated.
transcriptional assay involving fusion of Yki to the DNA binding domain of Gal4 (Huang et al., 2005) (Figure 7c ). These observations suggest that the WW domains are required for interaction with an unidentified nuclear co-factor that contributes to the activation of downstream genes.
Neighboring Ser residues influence Ser168 phosphorylation While examining potential phosphorylation sites within Yki, we discovered that the presence of Ser residues at þ 1 and þ 4 positions relative to Ser168 (for example, Ser169 and Ser172 of Drosophila Yki) is conserved among Yki and YAP proteins (Figure 6d ). These Ser residues do not conform to consensus Wts phosphorylation sites, and the lack of Wts-mediated phosphorylation in the Yki:V5 S111A,S168A,S250A mutant implies that they are not Wts sites. However, because of their proximity to Ser168, and the possibility that they might be phosphorylated by other kinases, we examined their influence on Ser168 phosphorylation. To facilitate specific examination of Ser168, we first focused on Yki-N, as it has better resolution on Phos-tag gels than full-length Yki, and only includes two of the three Wts sites. Yki-N:V5, with S169A,S172A or S169A, S172A mutations, was transfected into S2 cells in the presence and absence of additional Wts, Sav and Hpo. Interestingly, even without exogenous Wts, Sav and Hpo, a small fraction of the Yki-N-S169A, S172A double-or single-mutant proteins exhibited a mobility shift on Phos-tag gels (Figure 6e ), implying that Yki-N-S169A, S172A is a better substrate for phosphorylation by endogenous kinases in S2 cells than is wild-type Yki-N. Increased phosphorylation was also detected in the presence of Wts, Hpo and Sav, and was also detected using anti-phospho-Ser168 antisera (Figure 6e ).
To further investigate this, we introduced phosphomimetic mutations (Ser to Asp) at Ser169 and 172. In S2 cells transfected with Wts, Sav, Hpo and full-length Yki:V5, phosphorylation at Ser168 was decreased in a Yki:V5 S169D,S172D mutant ( Figure 6a ). Increased phosphorylation of Yki:V5 S169A,S172A was not obvious, but because this assay relies on detecting a stronger band, as opposed to a new band, it is not as sensitive as the Phostag gel assay. Co-IP experiments suggested that 14-3-3 proteins had increased affinity for Yki:V5 S169A,S172A
, and decreased affinity for Yki:V5 S169D,S172D
, consistent with phosphorylation changes at Ser168 (Figure 6a) .
To evaluate the activities of Yki:V5 S169A,S172A and Yki:V5 S169D,S172D in vivo, we generated transgenic flies, using the attP2(68A) insertion site. Similar to wild type, Yki:V5 S169A,S172A did not exhibit phenotypes when expressed under sd-Gal4 or GMR-Gal4 control, and resulted in irregular-shaped clones with almost no detectable nuclear localization (Figures 2e and 3q , and data not shown). Yki:V5 S169A,S172A had some activity, as it rescued the growth of yki B5 mutant clones when expressed under ci-Gal4 control (not shown). However, Yki:V5 S169A,S172A expressed under arm-Gal4 control was not able to rescue the lethality of yki B5 mutant flies. Moreover, co-expression of Yki:V5 S169A,S172A with UAShpo in eyes at relatively low levels (under GMR-Gal4 control, but at 18 1C, which lowers expression levels) results in lethality, whereas flies expressing wild-type Yki:V5 survived. These results suggest that Yki:V5 S169A,S172A S111A,S168A,S250A S111A,S168A,S250A-WW Relative Luciferase Activity Yorkie phosphorylation sites H Oh and KD Irvine is less active than wild-type Yki:V5. By contrast, Yki:V5 S169D,S172D exhibited mild overgrowths when expressed under sd-Gal4 or GMR-Gal4 control ( Figures  2g and 3r) , partial resistance to Hpo overexpression (Figures 3s and t) and increased nuclear localization (Figures 5q and r) . The severity of the overgrowth phenotypes placed it in between the Yki:V5 S111A and Yki:V5 S250A mutants, implying that phosphorylation of Ser168 is reduced, but not abolished. Direct examination using phospho-specific antibody showed that phosphorylation of Ser168 is reduced on Yki:V5 S169D,S172D in vivo (Figure 6b ). Thus, it is likely that if phosphorylation of Ser169 and 172 occurred, it would reduce Ser168 phosphorylation, thereby promoting Yki activity.
Discussion
Earlier studies identified multiple sites of Wts/Lats phosphorylation on Yki and YAP. Most attention has focused on a conserved site at Yki-Ser127/YAP-Ser168, which, when phosphorylated, forms a binding site for 14-3-3 proteins (Dong et al., 2007; Zhao et al., 2007; Oh and Irvine, 2008) . However, regulation of Yki/YAP by Wts/Lats cannot be fully accounted for by Ser127/YAPSer168 phosphorylation (Zhao et al., 2007; Hao et al., 2008; Oh and Irvine, 2008) . Mutation of the five consensus Lats phosphorylation sites within YAP had stronger effects on YAP localization and transcriptional activity in cultured mammalian cells than mutation of Ser127 alone (Zhao et al., 2007; Hao et al., 2008) , but the respective contributions of the different sites were not analyzed in detail. The results described here extend our understanding of Yki regulation in Drosophila by biochemically identifying all of the Wts phosphorylations sites within Yki, characterizing the respective contributions of each of these sites to Yki regulation, and providing insights into the mechanism by which phosphorylation sites regulate Yki activity. In addition, we have determined that the critical role of the WW domains in Yki is not to promote Yki phosphorylation, but rather to bind another factor that is positively required for Yki activity. A number of transcription factors contain PPXY motifs, including some that interact with YAP in mammalian cells, but further studies will be required to identify the relevant Drosophila WW-domain interacting Yki partner(s).
Taking all of the observations on Wts site mutants together, a consistent allelic series emerged in which the relative activity of different Yki isoforms was wild type oS111A oS250A oS111A,S250A oS168A oS111A, S168A ¼ S168A,S250Ao S111A,S168A,S250A. Phosphorylation of Ser111 and Ser250 clearly influences Wts activity, as mutation of Ser111 and Ser250, alone or in combination, hyperactivates Yki and makes Yki partially resistant to overexpression and activation of Wts, both when Ser168 is wild-type and when it is not. At the same time, the different Wts phosphorylation sites do not contribute equally-Ser 168 has the greatest influence. The observations that the double-mutant combinations have stronger phenotypes than singlemutant combinations and that the triple-mutant combination has the strongest phenotype indicate that the three sites act additively.
All three sites influence the subcellular localization of Yki. As either S111A,S250A double mutants or S168A mutants are predominantly cytoplasmic when there is sufficient active Wts, these sites can act independently to retain Yki in the cytoplasm. The amino-acid sequence around Ser168 conforms to a consensus 14-3-3 binding site (RXXSpXP), and binding between Yki and 14-3-3 proteins that depends on phospho-Ser168 has been established (Dong et al., 2007; Oh and Irvine, 2008) . The Wts phosphorylation sites at Ser111 and Ser250 do not conform to consensus 14-3-3 binding sites. A few exceptional cases of 14-3-3 binding to divergent sequences have been reported (reviewed in Fu et al., 2000) , but the requirement for Ser168 in 14-3-3 binding experiments (Dong et al., 2007; Oh and Irvine, 2008) implies that Ser111 and Ser250 do not mediate binding to 14-3-3 proteins. Thus, it is possible that phosphorylated Ser111 and Ser250 bind to some other cytoplasmic anchoring protein. Alternatively, it might be that Ser111 and Ser250 bind to 14-3-3 proteins, but with too low an affinity to be detected by co-immunoprecipitation experiments.
We also observed an unexpected influence of Ser250 and Ser111 on phosphorylation of Ser168. This suggests a model in which phosphorylation occurs in a complex that includes Yki, scaffolding proteins (for example, 14-3-3), and Wts, such that binding to the scaffold enhances further phosphorylation of Yki by Wts. This observation has implications for Yki/YAP-dependent oncogenesis, as it provides an additional mechanism by which mutations at secondary sites could influence Yki/YAP activity, and implies that the effects of such mutations could be detectable through an influence on Yki-Ser168/ YAP-Ser127 phosphorylation. Nonetheless, our studies indicate that Ser250 and Ser111 can also act independently to influence Yki. It is also worth emphasizing that the level of phosphorylation at Ser168 is higher in S111A,S250A double mutants than in S169D,S172D double mutants, but the former mutants have more severe overgrowth phenotypes. This further supports the conclusion that Ser111 and Ser250 can regulate Yki independently of their effect on Ser168 phosphorylation.
Our results emphasize that both the levels of Yki/YAP expression and its phosphorylation state are critical. When wild-type Yki is overexpressed, unless this overexpression is at very high levels, endogenous tumor suppressors can keep it in check. Conversely, most assays for oncogenic mutations in Yki/YAP have involved highlevel overexpression, but when an activating mutation was present (Ser168A) and expression was kept low by Gal80 co-expression, the effects were mild; strong overgrowth required either additional mutations or higher-level expression. In this regard, it is interesting that overexpression of YAP and/or amplification of the YAP locus has been identified in many cancers (Zender et al., 2006; Steinhardt et al., 2008; Zeng and Hong, 2008) . Thus, overexpression of YAP seems to act in concert with decreased phosphorylation of YAP (whether through mutations in YAP itself or through upstream tumor suppressors) to effect oncogenic transformation.
Finally, our results have raised the possibility of additional regulatory inputs into Yki/YAP phosphorylation. The presence of Ser residues at þ 1 and þ 4 positions relative to Yki-Ser168/YAP-Ser127 is highly conserved. Moreover, mutation of this site to a nonphosphorylatable amino acid was associated with a decrease in Yki activity, whereas mutation to a phosphomimetic amino acid was associated with Yki hyperactivity and decreased Ser168 phosphorylation. Although confirmation of the existence and importance of phosphorylation at these sites awaits the actual identification of relevant kinases, the discovery of these sites emphasizes that there may be additional regulatory inputs into Yki/ YAP regulation, with implications for growth control both during normal development and during oncogenesis.
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